Do you want to read an article? Please log in or register.
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
Macular Diseases
Related content
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
COMMENTED
Macular Diseases
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
JAMA Ophthalmol.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.
doi: 10.1001/
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.
COMMENTED
Macular DiseasesRetinal Diseases
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Creuzot-Garcher C, Miguel L, Alforja S, Sararols L, Casaroli-Marano RP, Zarranz-Ventura J, Gillies M, Arnold J, Barthelmes D
doi: 10.1111/aos.14893
Macular Diseases
Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
J Clin Med.
Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, Toro MD
doi: 10.3390/jcm9051522.
ConjunctivitisFlammer SyndromeMacular DiseasesRetinal DiseasesCataracts
12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
Acta Ophthalmol
Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, Guillemin M, Fraser-Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D
doi: 10.1111/aos.15014
Macular Diseases
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BMC Ophthalmol.
Waizel M, Todorova MG, Masyk M, Wolf K, Rickmann A, Helaiwa K, Blanke BR, Szurman P
doi: 10.1186/s12886-017-0471-x.
Macular DiseasesRetinal Diseases
Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
Int Ophthalmol.
Rouvas A, Chatziralli I, Androu A, Mpougatsou P, Alonistiotis D, Douvali M, Kabanarou SA, Theodossiadis P
doi: 10.1007/s10792-018-0833-2.
Macular Diseases
Aflibercept and navigated versus conventional laser in diabetic macular oedema: a 12-month randomized clinical trial
Acta Ophthalmol.
Blindbaek SL, Peto T, Grauslund J
doi: 10.1111/aos.14266.